Newbury Pharmaceuticals (NEWBRY) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 net revenue of SEK 21.1m, with both Nordic and international sales contributing strongly.

• Delivered first positive quarterly EBITDA of SEK 2.4m, meeting 2024 financial goal.

• Full-year net revenue rose to SEK 36.8m, up from SEK 10.3m year-over-year.

• Expanded product launches and marketing authorizations in the Nordics, with 13 products launched and 21 approved.

Financial highlights

• Q4 net revenue: SEK 21.1m (Q4 2023: SEK 2.8m); full-year: SEK 36.8m (2022/23: SEK 10.3m).

• Q4 EBITDA: SEK 2.4m (Q4 2023: SEK -4.5m); full-year EBITDA: SEK -12.3m (2022/23: SEK -18.3m).

• Q4 operating result (EBIT): SEK 1.9m (Q4 2023: SEK -4.8m); full-year EBIT: SEK -14.1m (2022/23: SEK -19.6m).

• Cash at period end: SEK 15.3m (2023: SEK 8.5m); equity: SEK 51.9m (2023: SEK 49.4m).

• Operating cash flow for the year: SEK -23.7m (2022/23: SEK -23.2m).

Outlook and guidance

• Plans to launch more than 13 products in the Nordics during 2025, aiming for continued annual sales growth.

• Anticipates sales fluctuations due to tender-driven business but maintains focus on growth and portfolio expansion.